Top down tandem mass spectrometric analysis of a chemically modified rough-type lipopolysaccharide vaccine candidate by Oyler, BL et al.
 Running Title: Top down LPS vaccine analysis 
Benjamin L. Oyler,1 Mohd M. Khan,1 Donald F. Smith,2 Erin M. Harberts,3 David P. A. Kilgour,4 Robert 
K. Ernst,3 Alan S. Cross,5 David R. Goodlett6 
 
1School of Medicine, University of Maryland, Baltimore, MD 21201 
2National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL  32310 
3Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 
21201 
4Chemistry and Forensics, School of Science & Technology, Nottingham Trent University, Nottingham, 
NG11 8NS, UK 
5Center for Vaccine Development, School of Medicine, University of Maryland, Baltimore, MD 21201 
6Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 
21201 
 
 
Address reprint requests to Prof. David R. Goodlett, Pharmacy Hall North Room 623, 20 N. Pine St, 
Baltimore, MD 21201, Phone: (410) 706-1490, Email: dgoodlett@rx.umaryland.edu 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Abstract 
Recent advances in lipopolysaccharide (LPS) biology have led to its use in drug discovery pipelines, 
including vaccine and vaccine adjuvant discovery. Desirable characteristics for LPS vaccine candidates 
include both the ability to produce a specific antibody titer in patients and a minimal host inflammatory 
response directed by the innate immune system. However, in-depth chemical characterization of most 
LPS extracts has not been performed; hence, biological activities of these extracts are unpredictable. 
Additionally, the most widely adopted workflow for LPS structure elucidation includes nonspecific 
chemical decomposition steps before analyses, making structures inferred and not necessarily biologically 
relevant. In this work, several different mass spectrometry workflows that have not been previously 
explored were employed to show proof-of-principle for top down LPS primary structure elucidation, 
specifically for a rough-type mutant (J5) E. coli-derived LPS component of a vaccine candidate. First, ion 
mobility filtered precursor ions were subjected to collision induced dissociation (CID) to define 
differences in native J5 LPS v. chemically detoxified J5 LPS (dLPS). Next, ultra-high mass resolving 
power, accurate mass spectrometry was employed for unequivocal precursor and product ion empirical 
formulae generation. Finally, MS3 analyses in an ion trap instrument showed that previous knowledge 
about dissociation of LPS components can be used to reconstruct and sequence LPS in a top down 
fashion. A structural rationale is also explained for differential inflammatory dose-response curves, in 
vitro, when HEK-Blue hTLR4 cells were administered increasing concentrations of native J5 LPS v. 
dLPS, which will be useful in future drug discovery efforts.  
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Introduction 
Lipopolysaccharide (LPS), also known as endotoxin, is a major component of the outer leaflet of most 
Gram-negative bacterial outer cell membranes [1, 2]. It is amphipathic, allowing it to interact with a wide 
range of ions and molecules to maintain cell membrane integrity [1], participate in cell-cell interactions 
[3 5], contribute to pathogenicity [6], and protect the bacterium from exogenous threats [7 10]. LPS is 
composed of three parts (listed in order from the membrane to the extracellular space): 1.) a lipophilic, 
multiply acylated diglucosamine membrane anchor that produces the canonical biologic activity of Gram-
negative bacterial infection (lipid A), 2.) a non-repeating oligosaccharide core (core OS), and 3.) a 
polysaccharide, composed of repeating oligosaccharide units, that produces an immunodominant antigen 
responsible for the O serotype (O-antigen). LPS exists as a mixture of biosynthetic products that can be 
broadly classified into two groups: rough-type LPS (R-LPS) or lipooligosaccharide (LOS), and smooth-
type LPS (S-LPS). S-LPS is a complete LPS molecule, comprising all three aforementioned parts, while 
R-LPS lacks the O-antigen portion, usually resulting in a loss of virulence. The biosynthesis pathway 
enzymes for making lipid A and core OS in Gram-negative bacteria are relatively well-conserved. 
However, due to differences in abundance or structure of LPS modifying enzymes, the resultant products 
from these syntheses can vary greatly, both in structure and function, even within one species [11]. Many 
non-stoichiometric substitutions of phosphate groups, sugars, amino acids, amines, and other R-groups 
are also observed in LPS extracts, making accurate structural analyses challenging. 
The dramatic increase in antibiotic resistance has left clinicians with fewer options to treat Gram-negative 
bacterial infections. Vaccines have proven to be one of the most efficient strategies to prevent infectious 
disease-related mortality and morbidity [12]. Although some of the structural features of LPS resulting in 
specific illnesses like sepsis have been established (e.g. lipid A-TLR4 ligand-receptor binding induced 
cytokine storm), there is no FDA-approved drug or vaccine against Gram-negative bacteria-induced 
sepsis in large part because anti-lipid A antibodies have not shown much promise in clinical settings [13
16]. Lipid A three dimensional (3D) structure is usually quite flexible and varies greatly between species 
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of Enterobacteriaceae; however, the 3D structure of core OS remains similar due to conservation of 
biosynthetic enzymes [1]. In the past, studies have drawn a correlation between survival after Gram-
negative bacterial sepsis and measured levels of circulating anti-core endotoxin antibodies in patient sera 
[17, 18]. Consequently, one feasible strategy for preventing sepsis is modification of LPS to generate 
antibodies to conserved epitopes in the core OS without eliciting a strong innate immune response. 
Passive infusion of immune sera after immunization of human volunteers with a vaccine composed of a 
heat-killed mutant of E. coli O111 which lacked the O polysaccharide (J5, or Rc chemotype mutant) 
resulted in protection against Gram-negative bacterial sepsis. A subsequent vaccine was developed using 
the purified J5 R-LPS that was alkali-treated to reduce the lipid A-induced toxicity and make the vaccine 
less reactogenic.  This detoxified J5 LPS (J5 dLPS) was non-covalently complexed with group B 
meningococcal outer membrane protein (OMP) to form a hydrophobic complex. The hydrophilic portion 
on the outer surface enhanced its solubility and delivery. When administered to rodents, it improved 
survival from polymicrobial sepsis [19 21] and was well tolerated in humans [22] where it elicited a 37
142-fold increase in anti-core LPS antibody titer post-vaccination [21].  Interestingly, anti-core LPS 
vaccines (e.g. J5 Bacterin®) have been successful in treating bovine mastitis and decreasing Gram-
negative bacterial sepsis incidence in animals [23, 24]. Additional vaccines have been developed against 
core OS but have not progressed to clinical trial [18, 25]. 
The core glycolipid-carrier protein complex or liposome-associated preparations have been developed to 
facilitate vaccine delivery and immunization processes as lipid A in liposomes imparts significantly 
reduced toxicity [26] and liposome-encapsulated TLR4 ligands produce higher antibody response [27]. 
Since LPS is highly reactogenic and can impart severe toxicity, chemical modification of LPS vaccines, 
such as the J5 vaccine, to reduce lipid A toxicity while retaining core OS immunogenicity has been 
proposed [21, 24]. In addition, the potent pro-inflammatory activity of the lipid A portion of the LPS has 
been modified to safely provide adjuvant activity for many vaccines. In fact, a chemically modified LOS, 
monophosphoryl lipid A (MPL®), that has diminished reactogenicity but potent adjuvanticity [28, 29] is 
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used as a vaccine adjuvant in GlaxoSmithKline
papillomavirus (HPV) vaccine Cervarix®. Recently, rationally designed lipid A-based Toll-like receptor 
4 (TLR4) ligands have been reported for vaccine adjuvant discovery and modulating the innate immune 
response [30, 31]. Given both the potential use of core OS as a vaccine and a modified lipid A as a 
vaccine adjuvant, LPS structure elucidation capability to support these efforts is critical. 
In the past, LPS has been mostly analyzed after hydrolysis into its three distinct components by mass 
spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, or most commonly, a combination 
of both techniques, and then reconstructed by inference representative
for a species or strain. The results from these experiments can be misleading for several reasons 
mentioned below; this list is not exhaustive. First  and most importantly  LPS extracts are always a 
mixture of very similar compounds, sometimes producing exactly isobaric ions, making exact data 
interpretation very difficult. This problem is compounded by relatively nonspecific methods like 
hydrolysis or solvolysis for dissociation. Mixture complexity inevitably increases when these methods are 
employed. Second, it is impossible, using this sub-component based structure definition approach, to infer 
which candidate LPS structures are actually present in the cell membrane and are consequently of 
biological relevance. Third, biological activities cannot be positively attributed to specific structures 
because the complete structures are unknown. Attribution of structure to activity, or structure-activity 
relationships (SAR), are also impossible to infer from mixtures of biologically active molecules unless the 
relative activities of each of the components, as well as any interactions they may have with one another, 
are known. Indeed, it has been shown that pure, chemically synthesized lipid As corresponding to 
molecular formulae found together in extracted E. coli lipid A mixtures cause markedly different cytokine 
responses in murine macrophages [32]. Therefore, even though the hypothesis has not been exhaustively 
tested, it is reasonable to work on the assumption that differences in activity between LPS extracts are 
cumulative, since any mixture of LPS molecules likely contains full agonists, partial agonists, and 
antagonists of TLR4. 
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Qureshi et al. showed that R-LPS could be purified based on the number of acyl chains present and 
analyzed offline by plasma desorption mass spectrometry in 1988 [33] et al. published 
a top down liquid chromatography-tandem MS approach to determining primary structural features of R-
LPS from E. coli laboratory strains using collision induced dissociation (CID) and ultraviolet 
photodissociation (UVPD) [34]. Although it has been feasible to perform top down tandem MS 
experiments on R-LPS researchers have opted for the divide-and-conquer approach 
of wet chemistry followed by MS analysis of the separate components. 
With advances in MS instrument hardware, software, and electronics have come substantial increases in 
mass spectrometer capabilities since the heyday of plasma desorption. Modern instruments have become 
more sensitive, can analyze many more samples in the same amount of time, and possess greater mass 
resolving powers and mass accuracies than older mass spectrometers. These benefits allow operators to 
separate, detect, and identify many ions solely in the gas phase. This approach was applied to the 
following research, using several different MS instruments for confirmation of previous results and to add 
complementary data for strengthened structural conclusions. Since the primary chemical structure of the 
J5 vaccine  has never been evaluated, and to investigate the hypothesis that the 
detoxified R-LPS vaccine from the J5 strain of E. coli derives its decreased inflammatory potential, while 
maintaining therapeutic value, from complete O-deacylation of the lipid A moiety, the following research 
was conducted: 
Experimental 
Materials 
Purified (low protein and nucleic acid content) and lyophilized LPS from E. coli J5 strain was 
purchased from both List Biological Laboratories, Inc. (Campbell, CA) and Sigma Aldrich (St. Louis, 
MO). Note: LPS can be toxic if ingested or inhaled; proper personal protective equipment should be 
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worn at all times. All solvents and water used throughout all experiments were Fisher (Waltham, MA) 
Optima LC/MS grade. 
Detoxification of R-LPS and preparation of vaccine 
To prepare a detoxified E. coli J5 LPS (J5 dLPS), purified LPS from List Biological Laboratories was 
re-suspended in water (4 mg mL-1) and an equal volume of 0.2 M NaOH solution was added slowly 
with gentle stirring, followed by heating in a water bath at 65 °C for 2 hours. The mixture was shaken 
every 5 minutes for the first hour and every 10 minutes thereafter. The solution was then neutralized 
with 1 M acetic acid, ethanol precipitated, and lyophilized to isolate the dry product. To prepare J5 
dLPS/group B meningococcal outer membrane protein (OMP) complex vaccine, OMP extracted from 
phenol-killed bacteria was mixed with J5 dLPS as described elsewhere [19, 22]. Briefly, OMP was 
extracted from phenol-killed bacteria by Empigen BB (Huntsman Corporation, The Woodlands, TX; 
licensed to Sigma Aldrich for sale) detergent. Extracted OMP was mixed with J5 dLPS (in 0.9% 
NaCl) at a ratio of 1.2:1 (w/w) in Tris-EDTA buffer, pH 8.0 containing 0.1% Empigen BB. Extensive 
dialysis was achieved to remove detergent and the vaccine was further filter sterilized and stored at 5 
°C. 
Cell culture and cytokine reporter assay 
HEK-Blue hTLR4 cells (Invitrogen, Waltham, MA
Medium (DMEM; Gibco, Gaithersburg, MD) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS; Sigma Aldrich, St. Louis, MO), 100 IU mL-1 penicillin, 100 µg mL-1 streptomycin, 1 
mM sodium pyruvate, and 200 mM L-glutamine in a humidified incubator at 37 °C, 5% CO2. For cell 
stimulation, lyophilized LPS was reconstituted in sterile, endotoxin-free water at a concentration of 1 
mg mL-1. This stock was serially diluted in DMEM before addition to the cell culture for the 
stimulation experiment. Post-stimulation (16 h), supernatants were collected from HEK-Blue cells, 
and the production of SEAP reporter was detected using Quanti-Blue (Invitrogen) according to the 
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- line stimulation data were plotted as the mean (± 
SD) from biological duplicates using GraphPad Prism 7.0 (La Jolla, CA). 
Defining mixture composition differences between intact and detoxified LPS samples 
Both intact J5 LPS and J5 dLPS samples from List Biological Laboratories, Inc. were dissolved in a 
solution, composed of 50% (v/v) 2-propanol and 50% water, and directly infused by syringe pump (5 
µL min-1, at an estimated concentration of 20 µg mL-1) into the source of a Waters (Milford, MA) 
Synapt G2 HDMS quadrupole-ion mobility separation-orthogonal acceleration time of flight mass 
spectrometer, equipped with a 4 kDa quadrupole, and operated with negative polarity electrospray 
Resolution  Traveling wave ion mobility separation (TWIMS) was 
employed to isolate ions with similar size, shape, and charge and to consequently simplify mass 
spectra. TWIMS was also used for gas-phase separation after quadrupole precursor isolation and prior 
to tandem MS experiments. The ion mobility separations were all performed using N2 as buffer gas at 
a flow rate of 90 mL min-1, with a wave velocity of 650 m s-1 and a wave height of 40.0 V. The ESI 
source was operated with a capillary potential of 3.00 kV, source temperature of 
cone at 40.0 V, source offset at 40.0 V, source gas (N2) flow at 0.0 mL min-1, desolvation temperature 
-1, desolvation gas flow at 400 L hr-1, and nebulizer gas pressure at 
5.0 bar. Collision induced dissociation (CID) tandem MS experiments were performed using ultra-
pure argon (Airgas, Radnor Township, PA) as collision gas, with manual collision energy ramping 
from 0 V to 100 V in increments of 10 V to produce comprehensive product ion spectra. All other 
instrument parameters are available upon request. 
Ultra-high mass resolving power, high mass accuracy FT-ICR MS to determine empirical formulae 
and define J5 LPS primary structure 
Intact E. coli J5 LPS from Sigma Aldrich (St. Louis, MO), dissolved in a solution of 50% 2-propanol 
and 50% water at an estimated total LPS concentration of 50 µg mL-1, was directly infused through a 
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home-built nano-electrospray ionization (nESI) source at a flow rate of 1 µL min-1 into a hybrid linear 
ion trap  21 Tesla Fourier transform-ion cyclotron resonance (FT-ICR) mass spectrometer, described 
in detail in a previous publication [35]. The ion spray was visually optimized for each experiment by 
adjusting capillary voltage and position while monitoring for constant signal as well as observation of 
a uniform electrospray plume. Multiple tandem MS experiments were performed, including trap CID, 
beam-type collisionally activated dissociation (beam CAD), and in-cell ultraviolet photodissociation 
(UVPD). Trap CID and beam CAD were performed with stepped collision energy. UVPD was carried 
out similarly to a previous publication [36] using a Coherent (Santa Clara, CA) Excistar XS ArF 
excimer laser operated at 193 nm wavelength and 522 µJ per pulse. The laser was previously aligned 
through a window in the rear of the ICR magnet housing on-axis with the ICR cell. 
Multi-stage MS (MSn) to confirm structural inferences 
Intact E. coli J5 LPS from both List Biological Laboratories, Inc. (Campbell, CA) and Sigma Aldrich 
(St. Louis, MO) were directly infused in a solution composed of 50% 2-propanol and 50% water at a 
flow rate of 2 µL min-1 into a home-built nESI source of a linear ion trap (linear trapping quadrupole; 
LTQ) mass spectrometer (Thermo Finnigan, San Jose, CA) with post-production ion funnel optics 
added for increased ion transmission efficiency. The mass spectrometer was operated in negative 
ionization mode with a capillary potential of 2.3 kV. Tandem MS experiments were performed in the 
ion trap with ultra-pure helium as collision gas. MS3 was carried out on product ions from LPS, 
corresponding to lipid A and core OS, at stepped normalized collision energies to evaluate its utility 
for top down sequencing. 
Data analysis 
Data acquired on the Synapt G2 HDMS instrument were initially processed in Driftscope version 2.7 
and MassLynx version 4.1 software (Waters, Milford, MA). When necessary, data were converted to 
mzML format using the ProteoWizard msconvert utility. Automated peak picking was performed 
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using mMass version 5.5 (www.mmass.org) [37]. Data acquired on the FT-ICR instrument were 
converted from magnitude mode to absorption mode and processed (including peak picking and 
absorption mode isotopic modeling) using AutoVectis (Spectroswiss Sàrl, Lausanne, Switzerland) 
[38 42]. For rapid visualization and spot checking of data, ICR mass spectra were saved as Thermo 
.raw files and manipulated in Thermo (San Jose, CA) Xcalibur version 3.0.63. Data acquired on the 
LTQ instrument were processed in Xcalibur version 3.0.63, and when necessary, were converted to 
mzML format for use in open source software suites. Peak picking for LTQ data was also performed 
using mMass version 5.5. Data were plotted using QtiPlot version 0.9.8.9 (www.qtiplot.com) and 
Figures were generated in Inkscape version 0.91 (https://inkscape.org) and when necessary, modified 
to an acceptable format using GIMP version 2.8.18 (www.gimp.org). 
Results and Discussion 
Cell culture and cytokine reporter assay 
To test the pro-inflammatory capacity of various LPS described in this manuscript, LPS were 
incubated with the HEK-
measured (Fig. 1). Both E. coli strains tested had similar stimulation profiles with J5 LPS reaching 
maximum stimulation at a slightly higher concentration than the W3110 strain. The J5 dLPS reached 
a lower maximum signaling level at a lower concentration, indicating that it is less inflammatory but 
maintained a strong binding affinity to the activated signaling pathway. The J5 dLPS/GBOMP 
formulation reached a similar maximal signaling level as the J5 dLPS but activation could be titrated 
down at a much higher concentration. PHAD, an adjuvant molecule already in use, stimulated cells at 
a much lower level than all other molecules tested, only rising above baseline at the highest 
concentration tested. At low concentrations J5 dLPS/GBOMP is capable of maintaining NF-
stimulation while PHAD, a known adjuvant molecule, is not. This novel method of detoxifying LPS 
could be used to create TLR4 agonists that are not toxic and still capable of stimulating the immune 
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system to a desirable level for adjuvant use. 
 
Fig. 1 Agonists were cultured with HEK-Blue hTLR4 cells over a 5-log dose range from 0.1-1000 ng 
mL-1. W3110 E. coli LPS (red), J5 E. coli LPS (orange), J5 dLPS (pink), J5 dLPS/GBOMP (green), 
or PHAD (blue) were incubated for 16 hours. Then NF- was measured by quantification 
of SEAP in the supernatant. Mean ± SD of duplicate samples and an associated 4-parameter non-
linear regression are shown 
Defining mixture composition differences between intact and detoxified LPS samples 
Direct infusion of J5 LPS and dLPS into the Synapt G2 HDMS produced many ions attributed to 
intact LPS and fragments thereof (Sup. Fig. 1). For the sake of simplicity, ions which could be easily 
E. coli LPS were isolated in the quadrupole, separated 
from isobars by ion mobility (Sup. Fig. 2), and subjected to CID  
collision cell by ramping collision energy and averaging the resultant tandem mass spectra. The 
precursor ions used for direct comparison (m/z 1071 for LPS and m/z 789 for dLPS) happened to have 
the largest complete LPS peak amplitudes and represented [M-3H]3- ions. 
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In the single stage mass spectrum of dLPS, there were no detectable ions corresponding to the 
complete R-LPS structure. This was interpreted to mean that the detoxification chemistry had 
proceeded to completion. After dissociation of J5 LPS and dLPS, one difference in the tandem mass 
spectra was immediately obvious: Liberated O-linked fatty acids were not present in dLPS product 
ion spectra (Fig. 2). The observation of low m/z product ions, including deprotonated fatty acids and 
phosphorous-containing ions, is a particular advantage to using a beam-type mass spectrometer for 
LPS tandem MS experiments rather than any quadrupolar ion trap mass analyzer because the 1/3 
cutoff rule, meaning product ions less than ~30% the m/z of the precursor ion are always unstable 
under trapping conditions, does not apply. These product ions can be directly diagnostic to structural 
changes in LPSs for which some structural information is already known. In aggregate, they can 
inform the analyst about which class of compound has been detected in an unknown. 
A total of 179 monoisotopic product ions were detected by the Synapt G2 HDMS above a signal to 
noise ratio (S:N) of 10:1 in the J5 LPS IMS-CID spectrum of m/z 1071; 221 were detected in the 
dLPS IMS-CID spectrum of m/z 789. Singly and doubly deprotonated product ions representing the 
full-length core OS (m/z 1418 and 708, respectively) were detected in both LPS and dLPS sample 
mass spectra, while the product ions representing the bis-phosphorylated, hexa-acylated E. coli lipid 
A (m/z 1796 and 897) were only present in the native LPS mass spectrum. Product ions assigned to 
the detoxified, di-acylated lipid A (m/z 951 and 475) were detected in the dLPS mass spectrum. These 
data further confirmed that the vaccine detoxification chemistry had proceeded as hypothesized. 
It is important to emphasize that both the LPS and dLPS samples produced heterogeneous mass 
spectra, even after crude IMS filtering, presumably due to many different LPS structures in the 
samples. Other analyses of R-LPS by both ESI-MS and MALDI-MS have demonstrated similar 
results [34, 43]. This means that the activity data shown in the previous section are cumulative and 
cannot be attributed to a particular R-LPS structure. However, the alkaline hydrolysis that was 
performed produced an entirely different mass spectrum than the commercial product. Since the mass 
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spectra are complex, quality control and quality assurance protocol development will be necessary to 
illustrate this need can be seen in Sup Fig 1. 
Second and third envelopes of ions were observed in the dLPS spectrum corresponding to differences 
in the number of core OS sugars. It is unclear from this study whether these differences were part of 
the original LPS mixture or if they were a result of the sample processing. 
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Fig. 2 Averaged IMS-CID tandem mass spectra of (a) J5 LPS m/z 1071 and (b) J5 dLPS m/z 789 after 
absence in (b) 
Ultra-high mass resolving power, high mass accuracy FT-ICR MS to determine empirical formulae 
and define J5 LPS primary structure 
In total, 252 unique, unambiguous monoisotopic masses were observed above a S:N of 10:1 in the 
Sigma J5 LPS sample with masses greater than the monoisotopic mass of KDO2-lipidIV A (J5 lipid A 
attached to two 2  4 linked 3-Deoxy-D-manno-oct-2-ulosonic acid residues through a 2  
glycosidic bond, [M] = 1844.971 Da), excluding redundant masses from additional charge states; 3-, 
4-, and 5- ions were observed for intact R-LPS (Sup. Table 1). One hundred ninety-six of these 
masses were larger than the mass of the canonical E. coli, hexa-acylated lipid A attached to five core 
OS sugars. Interestingly, thirty-six monoisotopic masses observed were greater than the mass of the 
intact, canonical J5 E. coli R-LPS. Some of these ions corresponded to empirical formulae for E. coli 
R-LPS with known substitutions such as phosphoethanolamine and phosphate/pyrophosphate. A few 
were inferred to be cation adducts of multiply deprotonated ions. The vast majority, however, were 
unable to be inferred using accurate mass alone. In short, the R-LPS mixture was very heterogeneous, 
including ions not previously described in the literature for E. coli R-LPS. One example of the 
heterogeneity observed in only a 4 m/z window is shown in Fig. 3. In this window, at least eight 
different monoisotopic masses were observed, at a mass resolving power of ~300,000 FWHM, in 
absorption mode. There was also not a single dominant species in the mixture as has sometimes been 
reported.  
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 Fig. 3 Zoomed negative mode FT-ICR mass spectrum (R ~ 300,000 FWHM, in absorption mode) 
after direct infusion of J5 LPS. Eight potential isotopic distribution envelopes can be identified in 
absorption mode in this 4 m/z window; these are denoted, at the m/z of their respective monoisotopic 
ions, with blue arrows. (inset) Magnified portion of the spectrum showing fine detail (including the 
magnitude mode and the proposed overlap between isotopologues from envelopes 2 and 5) 
The highest intensity complete R-LPS monoisotopic mass in the J5 LPS spectrum, as in the previous 
experiment, was m/z 1071.1976. This mass corresponded to a similar structure to that reported in [44, 
45] (Empirical formula: [C143H257N3O69P3]3- 0.139 ppm). The only differences observed were an 
addition of a phosphate moiety on the second heptose and a terminal glucosamine (GlcN) rather than 
an N-acetylglucosamine (GlcNAc). An ion was also observed in the spectrum at m/z 1085.2009, 
corresponding to the previously published structure with an added phosphate group (Empirical 
formula: [C145H259N3O70P3]3-,  = -0.381 ppm). An isolation of m/z 1071 prior to CID experiments 
resulted in an error of 0.064 ppm, in magnitude mode, for a single 0.767 second transient. 
Tandem MS experiments on m/z 1071 (3.5 m/z isolation) using trap CID, beam CAD, and UVPD all 
yielded feature-rich tandem mass spectra. Trap CID at normalized collision energy (NCE) of 30% 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
yielded 201 monoisotopic product ions above a S:N of 4:1. Six pairs of product ions (twelve ions 
total) were found to be duplications due to multiple charge states. Beam CAD at 35 V yielded 152 
product ions, with three pairs of duplicate identifications due to multiple charge states, using the same 
peak picking parameters. For many ions charge was not automatically identified, probably due to 
insufficient isotopic ion abundance. A wider precursor ion selection window and/or spectral 
averaging or summing would improve this statistic. Ninety-nine ions were detected in both trap CID 
and beam CAD experiments; either set of product ions was sufficient to confirm a hypothesized 
structure for the precursor ion (Fig. 4), when taking into account the cumulative effect of measuring 
every product ion at low ppb mass accuracy. These product ions corresponded to acyl chain 
cleavages, glycosidic bond cleavages, cross-ring cleavages, neutral losses of modifications, and 
combinations thereof. UVPD yielded ninety product ions, twenty-five of which were common to the 
CID and/or beam CAD experiments. et al  publication [34], a 
complementary set of product ions to those obtained through collisional activation. However, the 
efficiency of the UVPD process in this experiment was very low, so its value added would only be 
noticed with respect to very specific structural questions in this particular configuration and for this 
application (e.g. Are there hydroxylated fatty acyl chains in the lipid A moiety?). These types of 
questions are beyond the scope of this work. 
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 Fig. 4 Comparison of trap CID (blue) and beam CAD (red) for the same precursor ion at m/z 1071. 
Ninety-nine monoisotopic product ions common to both experiments were observed, fifteen of which 
are annotated in the CID mass spectrum with corresponding bond cleavages in the structure on the 
right. All product ion m/z were measured with less than 100 ppb error 
Multi-stage MS (MSn) to confirm structural inferences 
After conducting multiple product ion scans on intact R-LPS precursor ions, it became apparent that 
abundant product ions were always formed which corresponded to both the lipid A and core OS 
moieties. Since there have been many published papers describing dissociation phenomena for both 
chemically isolated lipid A [46 51] and oligosaccharides [52 56], it seemed that the logical next step 
would be to dissociate these products to determine whether MS3 product ions would be formed 
according to these well-established rules. If so, top down sequencing data interpretation and 
deconvolution for R-LPS would become much less challenging, and could be performed with 
confidence on nominal mass accuracy, low resolving power ion trap instruments.  
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Fig. 5 shows an MS3 experiment for both J5 lipid A (m/z 1796) and core OS (m/z 1418) ions formed 
in the ion trap after dissociation from intact R-LPS (m/z = 1071). Characteristic tandem mass spectra 
for both lipid A and core OS were obtained, suggesting the feasibility of simplified top down 
sequencing for both moieties and attribution of these to a specific LPS precursor. These data 
demonstrate that gas phase decomposition chemistry proceeds similarly to the widely adopted 
approach of solution phase decomposition followed by analyses of the reaction products separately. 
The primary benefit of the gas phase decomposition approach is that both lipid A and core OS can be 
directly attributed to a R-LPS structure present in the sample precluding the need for inference when 
analyzed separately. For lipid A, product ions indicative of neutral losses of ester-linked fatty acyl 
chains and metaphosphoric acid were the most abundant features in the mass spectra. For core OS, B- 
and Y- ions, as described by Domon and Costello [52], corresponding to glycosidic bond cleavages 
were the most abundant product ions, with minor product ions corresponding to cross-ring cleavages. 
It is likely that any MS3-capable trapping instrument, as well as beam-type instruments outfitted with 
post-CID ion mobility separation capability and subsequent secondary CID, will be able to perform a 
similar experiment. As in our previous work with lipid A [57], stepped or ramped collision energy at 
the MS3 level was able to simulate subsequent levels of MSn, with qualitatively minimal ion losses, to 
provide more complete dissociation and primary structure coverage for lipid A and core OS (data not 
shown). 
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 Fig. 5 MS3 CID mass spectra from MS2 product ions representing J5 E. coli lipid A at m/z 1796 (top) 
and core OS at m/z 1418 (bottom). Similar dissociation phenomena were observed as in MS2 
experiments for chemically isolated lipid A and oligosaccharides, indicating feasibility of LPS top 
down sequencing in this manner 
Conclusions 
As with all biologically active molecules, LPS activity is directly related to LPS structure. In this work, a 
chemically modified R-
result of O-deacylation of its lipid A moiety. Several different approaches were employed to more 
completely define structural features in commercially available, heterogeneous R-LPS mixtures. This 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
study has shown that R-LPS can be analyzed on three different mass spectrometers with similar but 
complementary results. Success of LPS-based drugs in the clinic will be partially dependent on well-
defined compositions of LPS extracts, if purification of single compounds or total chemical synthesis 
prove to be unfeasible, and batch-to-batch reproducibility of LPS production. This will inevitably lead to 
a better understanding of off-target effects and decrease probability of drug attrition. Reproducibility of 
immunological studies will also be improved through these efforts by improving quality control and 
quality assurance guidelines. In the past, this has been an onerous undertaking, but with improved data 
acquisition efficiency and the ability to acquire more complete data sets, the current rate limiting step is 
user-friendly, automated software development. 
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Legends for Figures 
Fig. 1 Agonists were cultured with HEK-Blue hTLR4 cells over a 5-log dose range from 0.1-1000 ng mL-
1. W3110 E. coli LPS (red), J5 E. coli LPS (orange), J5 dLPS (pink), J5 dLPS/GBOMP (green), or PHAD 
(blue) were incubated for 16 hours. Then NF- was measured by quantification of SEAP in 
the supernatant. Mean ± SD of duplicate samples and an associated 4-parameter non-linear regression are 
shown 
Fig. 2 Averaged IMS-CID tandem mass spectra of (a) J5 LPS m/z 1071 and (b) J5 dLPS m/z 789 after 
collision 
(b) 
Fig. 3 Zoomed negative mode FT-ICR mass spectrum (R ~ 300,000 FWHM, in absorption mode) after 
direct infusion of J5 LPS. Eight potential isotopic distribution envelopes can be identified in absorption 
mode in this 4 m/z window; these are denoted, at the m/z of their respective monoisotopic ions, with blue 
arrows. (inset) Magnified portion of the spectrum showing fine detail (including the magnitude mode and 
the proposed overlap between isotopologues from envelopes 2 and 5) 
Fig. 4 Comparison of trap CID (blue) and beam CAD (red) for the same precursor ion at m/z 1071. 
Ninety-nine monoisotopic product ions common to both experiments were observed, fifteen of which are 
annotated in the CID mass spectrum with corresponding bond cleavages in the structure on the right. All 
product ion m/z were measured with less than 100 ppb error 
Fig. 5 MS3 CID mass spectra from MS2 product ions representing J5 E. coli lipid A at m/z 1796 (top) and 
core OS at m/z 1418 (bottom). Similar dissociation phenomena were observed as in MS2 experiments for 
chemically isolated lipid A and oligosaccharides, indicating feasibility of LPS top down sequencing in 
this manner 
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